U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ABSOLUTE
Molecular Formula C10H15NO
Molecular Weight 165.2322
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TALSACLIDINE

SMILES

C#CCO[C@H]1CN2CCC1CC2

InChI

InChIKey=XVFJONKUSLSKSW-JTQLQIEISA-N
InChI=1S/C10H15NO/c1-2-7-12-10-8-11-5-3-9(10)4-6-11/h1,9-10H,3-8H2/t10-/m0/s1

HIDE SMILES / InChI

Molecular Formula C10H15NO
Molecular Weight 165.2322
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Talsaclidine (WAL-2014) is a selective full agonist of M1 muscarinic receptor, having partial agonist activity on the M2 and M3 subtypes (with no in vivo consequences). The general receptor profile of talsaclidine demonstrates a nearly specific interaction with muscarinic receptors, having only weak binding affinity for alpha1- and nicotinic receptors. The drug is being tested in phase III of clinical trials for the treatment of Alzheimer's disease.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
18.0 nM [EC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
2.7 ng/mL
0.5 mg single, oral
dose: 0.5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TALSACLIDINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
730 ng/mL
160 mg single, oral
dose: 160 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TALSACLIDINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
12 ng × h/mL
0.5 mg single, oral
dose: 0.5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TALSACLIDINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
4500 ng × h/mL
160 mg single, oral
dose: 160 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TALSACLIDINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
99%
TALSACLIDINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Memory-related task performance by aged rhesus monkeys administered the muscarinic M(1)-preferring agonist, talsaclidine.
2002 Jul
M1 muscarinic agonists can modulate some of the hallmarks in Alzheimer's disease: implications in future therapy.
2003
Treatment with the selective muscarinic m1 agonist talsaclidine decreases cerebrospinal fluid levels of A beta 42 in patients with Alzheimer's disease.
2003 Mar
Beta-secretase BACE1 is differentially controlled through muscarinic acetylcholine receptor signaling.
2004 Jul 15
Zinc uptake is mediated by M1 muscarinic acetylcholine receptors in differentiated SK-SH-SY5Y cells.
2006 Feb
Patents

Sample Use Guides

Talsaclidine is administered orally at a dose of 24 mg, three times a day.
Route of Administration: Oral
In Vitro Use Guide
Isolated tracheal muscle from guinea-pigs was incubated with 1-3000 uM of talsaclidine to test the muscarinic receptor agonism.
Substance Class Chemical
Created
by admin
on Mon Mar 31 19:23:17 GMT 2025
Edited
by admin
on Mon Mar 31 19:23:17 GMT 2025
Record UNII
1O8VSL798T
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
TALSACLIDINE
INN   WHO-DD  
INN  
Official Name English
Talsaclidine [WHO-DD]
Preferred Name English
talsaclidine [INN]
Common Name English
3-(2-PROPYNYLOXY)-1-AZABICYCLO(2.2.2)OCTANE, (R)-
Systematic Name English
Classification Tree Code System Code
NCI_THESAURUS C47796
Created by admin on Mon Mar 31 19:23:17 GMT 2025 , Edited by admin on Mon Mar 31 19:23:17 GMT 2025
Code System Code Type Description
FDA UNII
1O8VSL798T
Created by admin on Mon Mar 31 19:23:17 GMT 2025 , Edited by admin on Mon Mar 31 19:23:17 GMT 2025
PRIMARY
NCI_THESAURUS
C96885
Created by admin on Mon Mar 31 19:23:17 GMT 2025 , Edited by admin on Mon Mar 31 19:23:17 GMT 2025
PRIMARY
SMS_ID
100000083228
Created by admin on Mon Mar 31 19:23:17 GMT 2025 , Edited by admin on Mon Mar 31 19:23:17 GMT 2025
PRIMARY
EVMPD
SUB10814MIG
Created by admin on Mon Mar 31 19:23:17 GMT 2025 , Edited by admin on Mon Mar 31 19:23:17 GMT 2025
PRIMARY
INN
7270
Created by admin on Mon Mar 31 19:23:17 GMT 2025 , Edited by admin on Mon Mar 31 19:23:17 GMT 2025
PRIMARY
DRUG BANK
DB12287
Created by admin on Mon Mar 31 19:23:17 GMT 2025 , Edited by admin on Mon Mar 31 19:23:17 GMT 2025
PRIMARY
ChEMBL
CHEMBL2111051
Created by admin on Mon Mar 31 19:23:17 GMT 2025 , Edited by admin on Mon Mar 31 19:23:17 GMT 2025
PRIMARY
WIKIPEDIA
Talsaclidine
Created by admin on Mon Mar 31 19:23:17 GMT 2025 , Edited by admin on Mon Mar 31 19:23:17 GMT 2025
PRIMARY
CAS
147025-53-4
Created by admin on Mon Mar 31 19:23:17 GMT 2025 , Edited by admin on Mon Mar 31 19:23:17 GMT 2025
PRIMARY
PUBCHEM
71792
Created by admin on Mon Mar 31 19:23:17 GMT 2025 , Edited by admin on Mon Mar 31 19:23:17 GMT 2025
PRIMARY
EPA CompTox
DTXSID20163565
Created by admin on Mon Mar 31 19:23:17 GMT 2025 , Edited by admin on Mon Mar 31 19:23:17 GMT 2025
PRIMARY
Related Record Type Details
TARGET -> AGONIST
SALT/SOLVATE -> PARENT
TARGET->PARTIAL AGONIST
TARGET->PARTIAL AGONIST
Related Record Type Details
ACTIVE MOIETY